Evidence map›Paper›PMID 42411577›Full record

ArticlePulmonary medicine2026

Rapid Detection of Resistance Mutations in Multidrug-Resistant Tuberculosis With GenoType MTBDRsl Assay.

Shaina Gaikwad, Antisha Tiwari, Jitendra Singh, Alkesh Kumar Khurana, Sagar Khadanga, Shashank Purwar, Debasis Biswas, Anand Kumar Maurya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shaina GaikwadDepartment of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.ORCID https://orcid.org/0009-0003-1010-0224
Antisha TiwariDepartment of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.ORCID https://orcid.org/0009-0005-7453-3023
Jitendra SinghDepartment of Translational Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.ORCID https://orcid.org/0000-0001-5626-6076
Alkesh Kumar KhuranaDepartment of Pulmonary Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.ORCID https://orcid.org/0000-0002-7490-3953
Sagar KhadangaDepartment of General Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.ORCID https://orcid.org/0000-0002-8126-4459
Shashank PurwarDepartment of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.ORCID https://orcid.org/0000-0002-3542-2401
Debasis BiswasDepartment of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.ORCID https://orcid.org/0000-0002-7557-3693
Anand Kumar MauryaDepartment of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.ORCID https://orcid.org/0000-0002-4827-919X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultidrug-resistant tuberculosis (MDR-TB) is becoming a major threat to the global control of tuberculosis (TB). The situation worsens when fluoroquinolone (FQ) and second-line injectable (SLID) resistant strains are involved. This study assesses the utility of MTBDRsl V2.0 line probe assay (LPA) in identifying resistance patterns to FQ and SLID in MDR-TB isolates.

methodsA total of 74 MDR-TB isolates were tested for genetic mutations that confer resistance to FQs and against SLIDs by applying the GenoType MTBDRsl V2.0 LPA. This assay targets resistance-associated mutations in the gyrA and gyrB genes for FQ resistance, and in the rrs and eis genes for resistance to aminoglycosides and capreomycin.

resultsOf the 74 isolates examined, 14 (18.9%) had FQ resistance. Most of these isolates had mutations in the gyrA gene, most commonly at codon A90V (6.7%), followed by D94G (5.4%), and various D94 variations. No mutations were found in the rrs, gyrB, or eis genes, and no resistance to SLIDs was found. With no discernible contribution from rrs, gyrB, or eis genes, our results emphasize gyrA mutations, particularly A90V and D94G, as important molecular markers of FQ resistance.

conclusionThe MTBDRsl V2.0 assay demonstrated operational utility for rapid detection of resistance-associated mutations related to FQs and SLID drugs in MDR-TB isolates. Its rapid turnaround time expanded mutation coverage, and applicability in routine diagnostic settings make it a useful tool for molecular resistance profiling in high TB-burden settings.

Indexed as

Antitubercular AgentsDrug Resistance, Multiple, BacterialMutationMycobacterium tuberculosisTuberculosis, Multidrug-ResistantCapreomycinDNA GyraseFluoroquinolonesGenotypeHumansMicrobial Sensitivity TestsAntitubercular AgentsCapreomycinDNA GyraseFluoroquinolonesdrug resistance, GenoType MTBDRslmultidrug-resistant tuberculosis (MDR-TB)Mycobacterium tuberculosis (Mtb)

Identifiers

PMID42411577
PMCPMC13338885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.